Log in

Relevant bibliographies by topics / Remogliflozin

Contents

Journal articles

Academic literature on the topic 'Remogliflozin'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Remogliflozin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Remogliflozin"

1

Shinde, Sagar, Shweta Avhad, Vidya Morkar, Chaitanya Patki, Hemant Chikhale, and Laxmikant Borse. "Overview on remogliflozin SGLT-2 inhibitor in the management of type-2 diabetic mellitus in human beings." Bulletin of the Karaganda University. “Biology, medicine, geography Series” 112, no. 4 (2023): 156–67. http://dx.doi.org/10.31489/2023bmg4/156-167.

Full text

Abstract:

Sodium-glucose transport protein 2 inhibitors have become a significant category of oral medications in order to manage type 2 diabetic mellitus, particularly in people with heart disease or kidney disease, and have been highly advised overall current studies advice on how to treat. They can reduce blood pressure and help people lose weight, but they also come with drawbacks like genitourinary infections. The newly approved remogliflozin combinations are the product study of the pharmaceutical business for a new pharmaceutical class and novel drug combination with a view to managing diabetes.

APA, Harvard, Vancouver, ISO, and other styles

2

Gupta, Vishal Kumar, Deepak Pannu, Mahendra Pal Singh, and Lalit Kumar. "Effect of SGLT-2 inhibitor (remogliflozin) plus DPP4 inhibitor (vildagliptin) on diabetic nephropathy in patients with type 2 diabetes mellitus comparison with combination of metformin and sulphonylureas." International Journal of Advances in Medicine 10, no. 6 (2023): 446–51. http://dx.doi.org/10.18203/2349-3933.ijam20231450.

Full text

Abstract:

Background: Diabetes is leading cause of renal failure in entire world. Approximately 20-40 percent of patients with diabetes develop diabetic nephropathy. Newer drugs like SGLT-2 inhibitors and DPP-4 inhibitors are valuable option for Diabetic Nephropathy. Remogliflozin etabonate (RE) is the latest addition to the SGLT2 inhibitor class of drugs that have been recently approved in India for the management of T2DM.This study was conducted to elaborate effect of SGLT2 inhibitor (remogliflozin) plus DPP4 inhibitor (vildagliptin) on diabetic nephropathy in patients of Type 2 DM. Methods: This hosp

APA, Harvard, Vancouver, ISO, and other styles

3

Moumita, Hazra. "A Clinical Pharmacological Study on the Prevailing Prescription Patterns Appraisal of the Combination Therapies of Metformin and Remogliflozin, Metformin and Sitagliptin, and Metformin and Gemigliptin, among Early Grade Type II Diabetic Patients." International Journal of Toxicological and Pharmacological Research 12, no. 11 (2022): 31–38. https://doi.org/10.5281/zenodo.11421036.

Full text

Abstract:

<strong>Background: </strong>Oral hypoglycemic response is brought about through the activation of 5’ adenosine monophosphate induced protein kinase by metformin, inhibition of dipeptidyl peptidase-4 by the dipeptidyl peptidase-4 inhibitors, sitagliptin and gemigliptin, and the inhibition of a selective insulin-independent sodium glucose cotransporter subtype 2 by remogliflozin. <strong>Objectives: </strong>The objective of this clinical pharmacological study is the prevailing prescription patterns appraisal of the combination therapies of metformin and remogliflozin, metf

APA, Harvard, Vancouver, ISO, and other styles

4

Sreelatha, Gangu, Ramgondola V. Laxmi, Manne Nikshitha, and Orugala Amulya. "RP-HPLC Method Development and Validation for the Estimation of Antidiabetic Drugs Remogliflozin Etabonate and Vildagliptin in Bulk and Pharmaceutical Dosage Form." INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER) 6, no. 01 (2024): 1–7. http://dx.doi.org/10.37021/ijper.v6i1.01.

Full text

Abstract:

Introduction: The present study was done to develop a rapidand precise method by using reverse-phase high-performance liquid chromatography.Materials and Methods: This method was developed for the validation of Remogliflozin etabonate and vildagliptin in pharmaceutical dosage forms. Chromatography was carried out on a hypersil C18 (4.6×150 mm, 5 μm) column using a mixture of acetonitrile: Water (50:50% v/v) as mobile phase at a flow rate of 1.0 mL/min. The detection was carried out at 259 nm.Results: The retention times of remogliflozin etabonate and vildagliptin were found to be 2.344 and 3.2

APA, Harvard, Vancouver, ISO, and other styles

5

CS, Kagarana, Patel KN, and Patel AB. "Forced Degradation Method Development and Validation for Simultaneous Determination of Vildagliptin, Metformin Hydrochloride and Remogliflozin Etabonate in Bulk and its Formulation by RP-HPLC." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 01 (2024): 119–23. http://dx.doi.org/10.25258/ijpqa.15.1.19.

Full text

Abstract:

A simple and efficient stability-indicating method has been developed and validated for the simultaneous estimation of vildagliptin, metformin hydrochloride and remogliflozin etabonate in bulk and was applied on marketed formulations. KH2PO4 buffer (10 mM): Acetonitrile (70:30% v/v) at pH 5 was used as a mobile phase. Detection of drug peaks was at 215 nm by UV detector. The method was found to be linear in the concentration range of 2.5 to 7.5, 25 to 75 and 5 to 15 μg/mL for vildagliptin, metformin hydrochloride and remogliflozin etabonate, respectively. The limit of detection (LoD) and quant

APA, Harvard, Vancouver, ISO, and other styles

6

Markham, Anthony. "Remogliflozin Etabonate: First Global Approval." Drugs 79, no. 10 (2019): 1157–61. http://dx.doi.org/10.1007/s40265-019-01150-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sengupta, Soumya, Sunita Sengupta, and Sagar Katare. "A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus." International Journal of Research in Medical Sciences 9, no. 6 (2021): 1722. http://dx.doi.org/10.18203/2320-6012.ijrms20212242.

Full text

Abstract:

Background: The aim of the study was to evaluate effectiveness and safety of remogliflozin etabonate in a real-world outpatient setting in type 2 diabetes mellitus (T2DM) patients in India.Methods: A retrospective, observational, single-center study wherein medical records of adult patients (≥18 years old) with T2DM managed with remogliflozin 100 mg for at least three months at the diabetes care center in Jharkhand were retrieved. The effectiveness was assessed in terms of change from baseline in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), tota

APA, Harvard, Vancouver, ISO, and other styles

8

Attimarad, Mahesh, Katharigatta Narayanaswamy Venugopala, Anroop Balachandran Nair, Nagaraja Sreeharsha, and Pran Kishore Deb. "Experimental Design Approach for Quantitative Expressions of Simultaneous Quantification of Two Binary Formulations Containing Remogliflozin and Gliptins by RP-HPLC." Separations 9, no. 2 (2022): 23. http://dx.doi.org/10.3390/separations9020023.

Full text

Abstract:

The aim of this study was to develop a fast RP-HPLC method for simultaneous measurement of two antidiabetic formulations (vildagliptin + remogliflozin and teneligliptin + remogliflozin) under identical experimental conditions. Using the Box–Behnken approach and response surface design, the interaction and quadratic influence of three variable parameters, acetonitrile %, pH of the mobile phase, and flow rate, on resolution between the peaks were optimized. To forecast the resolution of peaks (2.7 and 6.5) for the three anti-diabetic medications, the design space with desirability function was u

APA, Harvard, Vancouver, ISO, and other styles

9

Nimmagadda, Rajya L., and Sowjanya Gummadi. "Concurrent Estimation of a Three Combination Type-2 Anti-diabetic Oral Dosage Form by Ultra-performance Liquid Chromatography." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 14, no. 04 (2023): 1171–77. http://dx.doi.org/10.25258/ijpqa.14.4.53.

Full text

Abstract:

Estimation of a three-combination dosage form containing metformin (MET), vildagliptin (VLDG), and remogliflozin etabonate (REMET) was performed by developing an economically simple and isocratic simultaneous method using ultra-performance liquid chromatograph (Alliance 1100 series) comprising of X-Bridge (50 × 4.6 mm, 2.5 μ) C18 column and photo diode array detector. 0.1 % v/v trifluoro acetic acid: acetonitrile (60:40% v/v) movable phase at 0.5 mL/min was used. The analytes were detected at a wavelength of 240.0 nm at 8.0 min. run time. The respective retention times of 1.004, 2.005, 5.118 m

APA, Harvard, Vancouver, ISO, and other styles

10

Sai, Prudhvi N. "NOVEL STABILITY INDICATING LC-MS/MS METHOD FOR THE SIMULTANEOUS ESTIMATION OF REMOGLIFLOZIN ETABONATE AND VILDAGLIPTIN HUMAN PLASMA." Journal of Medical pharmaceutical and allied sciences 10, no. 5 (2021): 3718–25. http://dx.doi.org/10.22270/jmpas.v10i5.1655.

Full text

Abstract:

The present study intended to develop an easy and novel Liquid Chromatography–Mass Spectrometry/Mass spectrometry (LC–MS/MS) method for simultaneous assay of remogliflozin etabonate and vildagliptin, a combined formulation used in treatment of type II diabetes in human plasma. Alogliptin drug was selected as internal standard and the analytes were isolated from the spiked plasma matrix using liquid-liquid extraction procedure and the extracts were chromatographed on Inertsil ODS (4.6 mm×100 mm, 5 μm) C18 column. The mobile phase comprises of methanol, acetonitrile and 0.1 % formic acid in 40:5

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!